"Citigroup Inc. lowered its price target for Human Genome Sciences Inc. (NASDAQ:HGSI) on Wednesday from $35 to $30, according to a research note.Citigroup also cut the firm’s rating from Buy to Hold.Human Genome Sciences researches and develops proprietary pharmaceutical and diagnostic products.The company's products predict, prevent, detect, treat, and cure disease based on the discovery of human and microbial genes.Human Genome Sciences has a potential upside of 44.4% based on a current price of $25.88 and an average consensus analyst price target of $37.38."